Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.
On 18-May-2026 Quantum BioPharma announced it has reached the half‑way enrollment milestone in its collaborative PET‑imaging study with Massachusetts General Hospital (MGH). The study uses the tracer [¹⁸F]3F4AP to detect demyelinated neurons in MS patients. Preliminary images from the first cohort show robust signals in acute MS lesions and potential sensitivity to gray‑matter lesions. The company expects this imaging approach to provide a real‑time, quantitative biomarker for myelin preservation and repair, directly aiding evaluation of its lead candidate Lucid‑MS (Lucid‑21‑302). The release quotes Dr. Andrzej Chruscinski (VP, Scientific & Clinical Affairs) and Dr. Pedro Brugarolas (MGH) highlighting the technique’s potential to transform MS disease monitoring.
This is an incremental but positive milestone. The MGH imaging study was already disclosed in late‑2025 and early‑2026; today’s news confirms it is progressing well and that early data are encouraging. There is no new regulatory decision, no financial infusion, and no unexpected scientific breakthrough. The market has been awaiting the FDA’s response to the IND (submitted in March 2026) as the next major catalyst, so this news is a routine – positive follow‑up rather than a material game‑changer. It modestly de‑risks the Lucid‑MS development pathway by validating a surrogate endpoint tool, but the heavy lifting for the stock will come from the IND clearance and Phase 2 trial start.
Quantum BioPharma Ltd. is a clinical‑stage biopharmaceutical company focused on neurodegenerative diseases, with a consumer‑wellness product line via its partially owned subsidiary Unbuzzd Wellness Inc.
* Lucid‑MS (Lucid‑21‑302) – a first‑in‑class, new chemical entity designed to inhibit demyelination by targeting protein arginine deiminase 2 (PAD2). It aims to provide neuroprotection in Multiple Sclerosis rather than immune modulation.
* Phase 1 trials completed with a favorable safety profile.
* IND submitted March 2026; Phase 2 trial planned soon after FDA clearance, with interim data targeted Q4 2026.
* MGH imaging study using [¹⁸F]3F4AP PET tracer is intended to provide a validated biomarker for treatment effect.
* Unbuzzd™ – a dietary supplement clinically shown to accelerate alcohol metabolism and reduce hangover symptoms. Quantum holds a 19.84 % stake in Unbuzzd Wellness Inc. and is entitled to a 7 % royalty on sales up to $250 M, then 3 % in perpetuity.
* Legal asset – a lawsuit against CIBC World Markets and RBC Dominion Securities alleging market manipulation (spoofing) with damages of up to $700 M. A motion to dismiss was largely denied, and a class action is also proceeding. Quantum has issued Contingent Value Rights to shareholders entitling them to 10‑50 % of net recoveries.